Alterity Therapeutics Ltd. · ASX:ATH
Alterity Therapeutics — Shareholder Meeting (November 2017)
8 slides from Alterity Therapeutics's shareholder meeting presentation, November 2017
Slide 1: Treatment of Neurological Disorders
Treatment of Neurological Disorders David Stamler, M.D. AGM 2017
Slide 2: Highlights
Highlights NOVEL DRUG CANDIDATE: PBT434 ▪ Targets key protein implicated in neurodegeneration of Parkinson’s disease and atypical parkinsonism ▪ Prevents accumulation and aggregation of α-synuclein ▪ Well tolerated in repeated dose toxicology studies STRONG RESEARCH AND DEVELOPMENT ▪ Innovative disc
Slide 3: Rapidly Growing Burden of Neurological Disease based on Aging Population
Rapidly Growing Burden of Neurological Disease based on Aging Population “Because the incidence of PD increases sharply with age and because the world’s population is aging, the number of individuals affected is poised for exponential growth.” Dorsey, Bloem. JAMA Neurology Published online November
Slide 4: PBT434 – Strong Development Rationale
PBT434 – Strong Development Rationale • PBT434 is a 2nd generation drug to emerge from Prana’s research program • Distinct chemical scaffold and biological profile compared to prior drug candidates • Excellent drug candidate based on physical characteristics • PBT434 targets α-synuclein, a biologica
Slide 5: α-Synuclein is an Important Disease Target
α-Synuclein is an Important Disease Target Strong Genetic and Pathological Link to Disease “Collectively these data strongly suggest that alpha synuclein is a potentially important and novel target of candidate neuroprotective therapies. Several different therapeutic strategies designed to clear or
Slide 6: PBT434 Lowers α-Synuclein and Prevents Neuronal Death
PBT434 Lowers α-Synuclein and Prevents Neuronal Death Transgenic Animal Model (hA53T) of PD ↓ α-Synuclein aggregation Preserves neurons in S. nigra Improves Motor Function * * 6 8 0 0 0 * * 1 0 0 n e u r o n s P < 0 .0 0 1 n y 4 C la s p in g - s T o ta l S N p c 4 0 0 0 T 5 0 3 5 2 A % h 0 0 0 V
Slide 7: Strategy Supported by Proof of Concept with Deferiprone
Strategy Supported by Proof of Concept with Deferiprone 6 month placebo controlled data in Parkinson’s disease patients Brain Iron by MRI Motor Function – UPDRS III DFP Fe binding Affinity Kb=1036 Improvement S. nigra S. nigra DFP PBO DFP PBO Reducing excess iron improves motor function Devos et al.
Slide 8: Summary
Summary • PBT434 targets α-synuclein, a biologically important protein implicated in neurodegenerative diseases • Iron is increased in the brain of patients with target diseases • PBT434 restores iron homeostasis and blocks the accumulation and aggregation of this protein • PBT434 has shown clear ef
Alterity Therapeutics — Shareholder Meeting (November 2017) on 6ix